214 related articles for article (PubMed ID: 34342024)
21. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
22. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
Stefanović NZ; Veličković-Radovanović RM; Danković KS; Mitić BP; Paunović GJ; Cvetković MB; Cvetković TP
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):749-760. PubMed ID: 32886348
[TBL] [Abstract][Full Text] [Related]
23. Effects of WuZhi preparations on tacrolimus in pediatric and adult patients carrying the CYP3A5*1 allele of heart transplant during the early period after transplantation.
Liu L; Zhou Y; Huang X; Chen H; Gong Z; Zhang J; Zeng F; Zhou H; Zhang Y
Clin Transplant; 2024 Jan; 38(1):e15237. PubMed ID: 38289887
[TBL] [Abstract][Full Text] [Related]
24. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
25. Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics.
Chen X; Wang DD; Xu H; Li ZP
Expert Rev Clin Pharmacol; 2020 May; 13(5):553-561. PubMed ID: 32452705
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
27. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
[TBL] [Abstract][Full Text] [Related]
28. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
[TBL] [Abstract][Full Text] [Related]
29. Multigene predictors of tacrolimus exposure in kidney transplant recipients.
Pulk RA; Schladt DS; Oetting WS; Guan W; Israni AK; Matas AJ; Remmel RP; Jacobson PA;
Pharmacogenomics; 2015 Jul; 16(8):841-54. PubMed ID: 26067485
[TBL] [Abstract][Full Text] [Related]
30. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
31. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
[TBL] [Abstract][Full Text] [Related]
32. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
[TBL] [Abstract][Full Text] [Related]
33. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
34. Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients.
Cheng F; Li Q; Wang J; Hu M; Zeng F; Wang Z; Zhang Y
Pharmgenomics Pers Med; 2021; 14():1463-1474. PubMed ID: 34824543
[TBL] [Abstract][Full Text] [Related]
35. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
Liu S; Chen RX; Li J; Zhang Y; Wang XD; Fu Q; Chen LY; Liu XM; Huang HB; Huang M; Wang CX; Li JL
Acta Pharmacol Sin; 2016 Sep; 37(9):1251-8. PubMed ID: 27498776
[TBL] [Abstract][Full Text] [Related]
36. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
37. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
38. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
39. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
Li DY; Teng RC; Zhu HJ; Fang Y
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
[TBL] [Abstract][Full Text] [Related]
40. Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients.
Liu M; Shaver CM; Birdwell KA; Heeney SA; Shaffer CM; Van Driest SL
Pharmacogenet Genomics; 2022 Jul; 32(5):209-217. PubMed ID: 35389944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]